|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fenoldopam#Nonclinical Toxicology]] |
| {{Fenoldopam}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Nonclinical Toxicology==
| |
| | |
| Carcinogenesis, Mutagenesis, Impairment of Fertility: In a 24-month study, mice treated orally with fenoldopam at 12.5, 25, or 50 mg/kg/day, reduced to 25 mg/kg/day on day 209 of study, showed no increase above controls in the incidence of neoplasms. Female mice in the highest dose group had an increased incidence and degree of severity of a fibro-osseous lesion of the sternum compared with control or low-dose animals. Compared to controls, female mice in the middle- and upper-dose groups had a higher incidence and degree of severity of chronic nephritis. These pathologic lesions were not seen in male mice treated with fenoldopam.
| |
| | |
| In a 24-month study, rats treated orally with fenoldopam at 5, 10 or 20 mg/kg/day, with the mid- and high-dose groups increased to 15 or 25 mg/kg/day, respectively, on day 372 of the study, showed no increase above controls in the incidence or type of neoplasms. Compared with the controls, rats in the mid- and high-dose groups had a higher incidence of [[hyperplasia ]]of collecting duct epithelium at the tip of the renal papilla.
| |
| | |
| Fenoldopam did not induce bacterial gene mutation in the Ames test or mammalian gene mutation in the Chinese hamster ovary (CHO) cell assay. In the in vitrochromosomal aberration assay with CHO cells, fenoldopam was associated with statistically significant and dose-dependent increases in chromosomal aberrations, and in the proportion of aberrant metaphases. However, no chromosomal damage was seen in the in vivo mice micronucleus or bone marrow assays.
| |
| | |
| Oral fertility and general reproduction performance studies in male and female rats at 12.5, 37.5 or 75 mg/kg/day revealed no impairment of fertility or reproduction performance due to fenoldopam.
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CORLOPAM (FENOLDOPAM MESYLATE) INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=df4cd207-c3b8-4008-5290-02f296c2b4a6 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| == References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Sympatholytic antihypertensives}}
| |
| {{Dopaminergics}}
| |
| | |
| [[Category:Benzazepines]]
| |
| [[Category:D1-receptor agonists]]
| |
| [[Category:Phenols]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |